ALR Technologies Inc. (ALRTF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ALRTF representa a ALR Technologies Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 54/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026ALR Technologies Inc. (ALRTF) Resumen de Asistencia Médica y Tuberías
ALR Technologies Inc. provides diabetes care solutions, including data management systems and continuous glucose monitoring (CGM) for humans and animals. Targeting healthcare providers and insurers, the company offers tools for data collection, predictive A1C, and remote monitoring, positioning itself in the evolving diabetes management market.
Tesis de Inversión
ALR Technologies Inc. presents a focused play on the diabetes management market, targeting both human and animal health. The company's Diabetes Management System and CGM offerings address the growing need for comprehensive diabetes care solutions. A key value driver is the potential expansion of their GluCurve Pet CGM in the veterinary market, tapping into the increasing awareness and treatment of diabetes in pets. However, the company's negative P/E ratio of -1.35 and a significantly negative profit margin of -159306.4% raise concerns about its financial sustainability. Future growth hinges on successful market penetration and achieving profitability. Investors should closely monitor revenue growth, cost management, and the adoption rate of their pet-focused CGM solution.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.01B indicates a micro-cap company with high growth potential but also higher risk.
- Gross Margin of 66.2% suggests a strong ability to control production costs relative to revenue.
- Negative P/E ratio of -1.35 reflects current unprofitability, requiring careful evaluation of future earnings potential.
- Profit Margin of -159306.4% indicates significant operational challenges and the need for improved cost management.
- Beta of 2.56 suggests high volatility compared to the market, indicating a riskier investment.
Competidores y Pares
Fortalezas
- Comprehensive Diabetes Management System.
- Unique GluCurve Pet CGM product for animal health.
- Focus on data-driven insights and remote monitoring.
- Integrated system for both human and animal diabetes care.
Debilidades
- Negative profit margin and reliance on external funding.
- Limited market presence and brand recognition.
- Small number of employees and limited resources.
- Dependence on the success of a few key products.
Catalizadores
- Upcoming: Potential partnerships with veterinary clinics to expand GluCurve Pet CGM sales.
- Upcoming: Development of new features and functionalities for the Diabetes Management System.
- Ongoing: Increasing awareness of diabetes in pets driving demand for GluCurve Pet CGM.
- Ongoing: Growing adoption of remote monitoring and data-driven diabetes management solutions.
Riesgos
- Potential: Competition from established players in the diabetes care market.
- Potential: Regulatory changes and healthcare reforms impacting product approvals and reimbursement.
- Potential: Technological advancements that could render their products obsolete.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: Negative profit margin and challenges in achieving profitability.
Oportunidades de crecimiento
- Expansion of GluCurve Pet CGM: The market for pet diabetes care is growing, driven by increased pet ownership and awareness of pet health. ALR Technologies' GluCurve Pet CGM addresses a specific need in this market, offering veterinarians a tool for effective diabetes management in cats and dogs. Successful market penetration and partnerships with veterinary clinics could significantly boost revenue. The pet diabetes care market is projected to reach $1.5 billion by 2028.
- Adoption of Diabetes Management System: The Diabetes Management System offers a comprehensive solution for healthcare providers and insurers. Increased adoption of this system can drive revenue growth. The global diabetes management market is expected to reach $25 billion by 2027, driven by the rising prevalence of diabetes and the need for effective management tools. ALR Technologies can capitalize on this trend by demonstrating the system's effectiveness in improving patient outcomes and reducing healthcare costs.
- Partnerships with Healthcare Providers: Collaborating with healthcare providers and integrating their solutions into existing healthcare systems can expand ALR Technologies' reach. Strategic partnerships can provide access to a wider patient base and enhance the credibility of their products. The healthcare IT market is growing rapidly, with a focus on interoperability and data-driven solutions. ALR Technologies can leverage this trend by offering seamless integration with existing healthcare platforms.
- Development of Prediabetes System: The Prediabetes System, with its educational content and online community, can attract a significant user base. By providing valuable resources and support, ALR Technologies can help individuals manage their prediabetes and potentially prevent the onset of type 2 diabetes. The prediabetes market is largely untapped, presenting a significant opportunity for growth. Early intervention and lifestyle management programs are gaining traction, creating a demand for solutions like ALR Technologies' Prediabetes System.
- Geographic Expansion: While currently focused on the United States, ALR Technologies can explore opportunities to expand its market reach to other countries. The global diabetes market is vast, and international expansion can significantly increase revenue. Emerging markets with growing diabetes prevalence offer particularly attractive opportunities. However, navigating regulatory requirements and cultural differences in different countries will be crucial for successful expansion.
Oportunidades
- Expanding GluCurve Pet CGM sales in the growing pet health market.
- Partnering with healthcare providers and insurers.
- Developing new features and functionalities for the Diabetes Management System.
- Expanding into new geographic markets.
Amenazas
- Competition from established players in the diabetes care market.
- Regulatory changes and healthcare reforms.
- Technological advancements that could render their products obsolete.
- Economic downturns that could reduce healthcare spending.
Ventajas competitivas
- Specialized focus on both human and animal diabetes care.
- Proprietary Diabetes Management System with data-driven insights.
- GluCurve Pet CGM addresses a specific need in the veterinary market.
- Integrated system combining data collection, monitoring, and support.
Acerca de ALRTF
ALR Technologies Inc., initially named Mo Betta Corp. before rebranding in 1998, was founded in 1987 and is headquartered in Richmond, Virginia, operating as a subsidiary of ALR Technologies SG Ltd. The company focuses on developing data-driven diabetes care solutions for both human and animal health markets. Their core product is the Diabetes Management System, a comprehensive platform that integrates data collection, predictive A1C calculations, insulin dosage suggestions, performance tracking, and remote monitoring. This system also includes diabetes test supplies. ALR Technologies also offers Continuous Glucose Monitoring (CGM) devices for real-time blood sugar readings in humans. Recognizing a gap in the animal health market, they developed GluCurve Pet CGM, specifically designed for feline and canine diabetes management, targeting veterinary professionals. Furthermore, ALR Technologies provides a Prediabetes System, featuring educational videos, mobile-friendly content, and an online community to support patients in managing prediabetes. The company's primary customer base includes healthcare providers, health insurance companies, and providers of disease and case management services, including the home care industry.
Qué hacen
- Develops Diabetes Management System for data collection and analysis.
- Offers predictive A1C calculations and insulin dosage suggestions.
- Provides Continuous Glucose Monitoring (CGM) devices for human use.
- Manufactures GluCurve Pet CGM for diabetes management in cats and dogs.
- Creates Prediabetes System with educational videos and online community.
- Offers remote monitoring and performance tracking solutions for diabetes care.
- Provides diabetes test supplies as part of its comprehensive system.
Modelo de Negocio
- Sells Diabetes Management System to healthcare providers and insurers.
- Generates revenue from the sale of CGM devices and related supplies.
- Offers GluCurve Pet CGM to veterinarians for animal diabetes management.
- Provides Prediabetes System subscriptions and related content.
Contexto de la Industria
ALR Technologies Inc. operates within the medical device industry, specifically targeting the diabetes care market. This market is driven by the increasing prevalence of diabetes globally, creating a demand for innovative monitoring and management solutions. The competitive landscape includes established players offering CGMs and diabetes management platforms. ALR Technologies differentiates itself by focusing on both human and animal health, with its GluCurve Pet CGM addressing a niche market. The industry is also influenced by technological advancements in remote monitoring and data analytics, which are integral to ALR Technologies' offerings.
Clientes Clave
- Healthcare providers (doctors, clinics, hospitals)
- Health insurance companies
- Veterinarians and animal health clinics
- Individuals with diabetes or prediabetes
Finanzas
Gráfico e información
Precio de la acción de ALR Technologies Inc. (ALRTF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para ALRTF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ALRTF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ALRTF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ALRTF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Sidney S. Chan
CEO
Sidney S. Chan is the CEO of ALR Technologies Inc. His background includes experience in managing and growing technology-focused companies. He is responsible for the overall strategic direction and operational execution of the company. He leads a small team of 7 employees, focusing on developing and marketing diabetes care solutions for both human and animal health. His expertise lies in identifying market opportunities and driving product innovation.
Historial: Under Sidney Chan's leadership, ALR Technologies Inc. has focused on expanding its product offerings in the diabetes care market, including the development of the GluCurve Pet CGM. Key milestones include securing partnerships with veterinary clinics and expanding the reach of the Diabetes Management System. However, the company's financial performance remains a challenge, with ongoing efforts to improve profitability and secure additional funding.
Información del mercado OTC de ALRTF
The OTC Other tier, where ALR Technologies Inc. trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is distinct from exchanges like NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Companies on OTC Other may be subject to less regulatory oversight, increasing investment risk.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in ALRTF.
- Lower liquidity can make it difficult to buy or sell shares at desired prices.
- The OTC Other tier is associated with higher risk of fraud and manipulation.
- Lack of regulatory oversight compared to listed exchanges.
- Potential for delisting or trading suspension due to non-compliance.
- Verify the company's registration and legal standing.
- Review available financial statements, if any, and assess their accuracy.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and potential trading risks.
- Consult with a financial advisor before investing.
- Be aware of the risks associated with investing in OTC stocks.
- The company has been in operation since 1987.
- ALR Technologies Inc. has a specific focus on diabetes care solutions.
- The company has developed products for both human and animal health.
- The company operates as a subsidiary of ALR Technologies SG Ltd.
Acciones de ALR Technologies Inc.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar ALRTF?
ALR Technologies Inc. (ALRTF) actualmente tiene una puntuación IA de 54/100, indicando puntuación moderada. Fortaleza clave: Comprehensive Diabetes Management System.. Riesgo principal a monitorear: Potential: Competition from established players in the diabetes care market.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ALRTF?
ALRTF actualmente puntúa 54/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ALRTF?
Los precios de ALRTF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ALRTF?
La cobertura de analistas para ALRTF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ALRTF?
Las categorías de riesgo para ALRTF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established players in the diabetes care market.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ALRTF?
La relación P/E para ALRTF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ALRTF sobrevalorada o infravalorada?
Determinar si ALR Technologies Inc. (ALRTF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ALRTF?
ALR Technologies Inc. (ALRTF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available for OTC-traded companies.
- Financial data based on available information and may not be comprehensive.
- Analyst consensus and price targets may not be available due to limited coverage.